| Members |
targetComponentId |
| Acute myelofibrosis |
Acute megakaryoblastic leukemia |
| Acute myelofibrosis |
Primary myelofibrosis |
| Acute myelofibrosis |
Myelodysplastic neoplasm with biallelic TP53 inactivation |
| Administration of prescribed antibiotic therapy and immunizing agents |
Administration of substance to produce immunity, either active or passive (procedure) |
| Administration of prescribed antibiotic therapy and immunizing agents |
Administration of antibiotic |
| Allergy: [allergic rhinitis due to other allergens] or [named animals or animal products] or [hay fever] or [house dust] |
Allergic rhinitis due to pollen |
| Allergy: [allergic rhinitis due to other allergens] or [named animals or animal products] or [hay fever] or [house dust] |
Allergy to animal protein |
| Allergy: [allergic rhinitis due to other allergens] or [named animals or animal products] or [hay fever] or [house dust] |
Allergy to house dust (finding) |
| protéine animale et allergène épidermique |
Animal protein |
| protéine animale et allergène épidermique |
Animal material |
| Animal protein and epidermal substance |
Animal material |
| Animal protein and epidermal substance |
Animal protein |
| Any T/Any N and M1 (IV): Distant metastasis including presence of malignant cells in pleural fluid or parenchymal hepatic metastasis (TNM category and FIGO stage) (fallopian tube) |
American Joint Committee on Cancer allowable value |
| Any T/Any N and M1 (IV): Distant metastasis including presence of malignant cells in pleural fluid or parenchymal hepatic metastasis (TNM category and FIGO stage) (fallopian tube) |
American Joint Committee on Cancer cM1 (qualifier value) |
| chorée de Bergeron |
Dissociative motor disorder |
| chorée de Bergeron |
Dissociative neurological symptom disorder co-occurrent with chorea |
| Blind hypotensive eye |
Phthisis bulbi |
| Blind hypotensive eye |
Atrophy of globe of eye |
| Blind hypotensive eye |
Phthisis bulbi |
| Blind hypotensive eye |
Atrophy of globe of eye |
| Chronic symmetrical impetigo |
Impetigo |
| Chronic symmetrical impetigo |
Ecthyma |
| drainage de l'espace intracrânien, subarachnoïdien ou subdural par incision ou trépanation |
Drainage of cerebral epidural space by incision or trephination |
| Drainage of intracranial space, subarachnoid or subdural by incision or trephination |
Drainage of cerebral subdural space by incision or trephination |
| drainage de l'espace intracrânien, subarachnoïdien ou subdural par incision ou trépanation |
Drainage of cerebral subdural space by incision or trephination |
| Drainage of intracranial space, subarachnoid or subdural by incision or trephination |
Drainage of cerebral subarachnoid space by incision or trephination |
| drainage de l'espace intracrânien, subarachnoïdien ou subdural par incision ou trépanation |
Drainage of cerebral subarachnoid space by incision or trephination |
| Drainage of intracranial space, subarachnoid or subdural by incision or trephination |
Drainage of cerebral epidural space by incision or trephination |
| Dupuytren's contracture |
Focal fibromatosis |
| Dupuytren's contracture |
Contracture |
| Dupuytren's contracture |
Fibrous bands |
| Early onset generalized periodontitis |
Aggressive periodontitis |
| Early onset generalized periodontitis |
Periodontitis as manifestation of systemic disease (disorder) |
| Early onset localized periodontitis |
Aggressive periodontitis |
| Early onset localized periodontitis |
Periodontitis as manifestation of systemic disease (disorder) |
| Early onset periodontitis |
Aggressive periodontitis |
| Early onset periodontitis |
Periodontitis as manifestation of systemic disease (disorder) |
| Echogynography |
US gynaecology scan |
| Echogynography |
Ultrasound procedure on female genital system AND/OR pregnancy related structure |
| artères nasales postérieure, latérale et septale entières |
Entire lateral nasal artery (body structure) |
| artères nasales postérieure, latérale et septale entières |
Entire dorsal nasal artery |
| personne apparentée handicapée |
Family history of learning disability |
| personne apparentée handicapée |
Family history of disability |
| personne apparentée handicapée |
Family history of intellectual disability |
| Fetus or neonate affected by ectopic pregnancy NOS |
Ectopic pregnancy |
| Fetus or neonate affected by ectopic pregnancy NOS |
Combined pregnancy |
| Fetus or neonate affected by unspecified ectopic pregnancy |
Ectopic pregnancy |
| Fetus or neonate affected by unspecified ectopic pregnancy |
Combined pregnancy |
| glucagonome |
Glucagonoma of uncertain behavior (morphologic abnormality) |
| glucagonome |
Malignant glucagonoma of pancreas (disorder) |
| Handicapped aids (& for severely handicapped) |
Provision of aid for severe disability |
| Handicapped aids (& for severely handicapped) |
Provision of aid for disability (procedure) |
| Handicapped: [relative - physically] or [spouse] or [child] |
Family history of disability |
| Handicapped: [relative - physically] or [spouse] or [child] |
Spouse has disability (situation) |
| Handicapped: [relative - physically] or [spouse] or [child] |
Child of subject has disability (situation) |
| Hysterical fever |
Pyrexia of unknown origin |
| Hysterical fever |
Factitious fever |
| Hysterical macropsia |
Dissociative neurological symptom disorder with visual symptom (disorder) |
| Hysterical macropsia |
Macropsia (disorder) |
| Hysterical micropsia |
Micropsia (disorder) |
| Hysterical micropsia |
Dissociative neurological symptom disorder with visual symptom (disorder) |
| Lansoprazole 15mg m/r capsule/naproxen 250mg tablet |
Product containing precisely naproxen (as naproxen sodium) 250 milligram/1 each conventional release oral tablet (clinical drug) |
| Lansoprazole 15mg m/r capsule/naproxen 250mg tablet |
Product containing precisely lansoprazole 15 milligram/1 each gastro-resistant oral capsule (clinical drug) |
| Lansoprazole 15mg m/r capsule/naproxen 375mg tablet |
Product containing precisely naproxen (as naproxen sodium) 375 milligram/1 each conventional release oral tablet (clinical drug) |
| Lansoprazole 15mg m/r capsule/naproxen 375mg tablet |
Product containing precisely lansoprazole 15 milligram/1 each gastro-resistant oral capsule (clinical drug) |
| Lansoprazole 15mg m/r capsule/naproxen 500mg tablet |
Product containing precisely lansoprazole 15 milligram/1 each gastro-resistant oral capsule (clinical drug) |
| Lansoprazole 15mg m/r capsule/naproxen 500mg tablet |
Product containing precisely naproxen (as naproxen sodium) 500 milligram/1 each conventional release oral tablet (clinical drug) |
| Large visual image |
Dissociative neurological symptom disorder with visual symptom (disorder) |
| Large visual image |
Macropsia (disorder) |
| Localized prepubertal periodontitis |
Aggressive periodontitis |
| Localized prepubertal periodontitis |
Periodontitis as manifestation of systemic disease (disorder) |
| Metastases by primary malignancy |
Primary malignant neoplasm (disorder) |
| Metastases by primary malignancy |
Metastatic malignant neoplasm (disorder) |
| Naproxen 500mg tablet and misoprostol 200micrograms tablet pack |
Product containing precisely naproxen (as naproxen sodium) 500 milligram/1 each conventional release oral tablet (clinical drug) |
| Naproxen 500mg tablet and misoprostol 200micrograms tablet pack |
Product containing precisely misoprostol 200 microgram/1 each conventional release vaginal tablet (clinical drug) |
| Naproxen 500mg tablet and misoprostol 200micrograms tablet pack |
Product containing precisely misoprostol 200 microgram/1 each conventional release oral tablet (clinical drug) |
| Necrotizing ulcerative gingivoperiodontitis |
Necrotizing ulcerative gingivitis (disorder) |
| Necrotizing ulcerative gingivoperiodontitis |
Necrotising ulcerative periodontitis |
| Overriding left ventriculoarterial valve |
Aortic valve overriding ventricular septum (disorder) |
| Overriding left ventriculoarterial valve |
Overriding aorta |
| Perception hysteria |
Absence of sensation due to conversion disorder |
| Perception hysteria |
Disturbance of perception associated with conversion and dissociative phenomenon |
| Porous impregnated material for conventional release vapor inhalation |
Porous impregnated material for oromucosal vapour inhalation |
| Porous impregnated material for conventional release vapor inhalation |
Porous impregnated material for conventional release pulmonary vapor inhalation (dose form) |
| Prepubertal generalized periodontitis |
Aggressive periodontitis |
| Prepubertal generalized periodontitis |
Periodontitis as manifestation of systemic disease (disorder) |
| Prepubertal periodontitis |
Aggressive periodontitis |
| Prepubertal periodontitis |
Periodontitis as manifestation of systemic disease (disorder) |
| Pressure collapse of lung after anesthesia AND/OR sedation in labor AND/OR delivery |
Pressure collapse of lung due to anaesthesia during pregnancy |
| Pressure collapse of lung after anesthesia AND/OR sedation in labor AND/OR delivery |
Pressure collapse of lung due to anesthesia during labor and delivery (disorder) |
| Pressure collapse of lung after anesthesia AND/OR sedation in labor AND/OR delivery |
Pressure collapse of lung due to anesthesia in puerperium |
| Product containing precisely etanercept 50 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Product containing precisely etanercept 51.02 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Product containing precisely etanercept 50 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Etanercept 49.01 mg/mL solution for injection |
| Small visual image |
Micropsia (disorder) |
| Small visual image |
Dissociative neurological symptom disorder with visual symptom (disorder) |
| Structure of posterior, lateral and septal nasal arteries |
Structure of dorsal nasal artery |
| Structure of posterior, lateral and septal nasal arteries |
Lateral nasal artery |
| T3 and/or N1 (III): Fallopian tube tumor involves one or both tube(s) with peritoneal implants outside the pelvis and/or regional lymph node metastasis |
cN1 |
| T3 and/or N1 (III): Fallopian tube tumor involves one or both tube(s) with peritoneal implants outside the pelvis and/or regional lymph node metastasis |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3 and/or N1 (III): Ovarian tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3 and/or N1 (III): Ovarian tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis |
cN1 |
FHIR